Research Results from Johns Hopkins University School of Medicine Update Knowledge of Health and Medicine (Psychedelic medicine: mechanisms, evidence, and translation to practice).

This article focuses on recent research into psychedelic treatments, specifically psilocybin and 3,4-methylenedioxymethamphetamine (MDMA), which have progressed to phase 3 clinical trials for psychiatric conditions. The review highlights their potential mechanisms involving neural circuitry and psychological flexibility, with strongest evidence supporting psilocybin for treatment-resistant depression and MDMA for post-traumatic stress disorder. Challenges identified include methodological limitations, the need for extensive therapeutic support, and issues with scalability and diverse patient inclusion. Future research priorities emphasize standardizing adverse event assessments, developing implementation guidelines, and demonstrating long-term benefits across varied populations. [Extracted from the article]